[ad_1]
| Company | Value | Change | %Change |
|---|
The company’s net profit before exceptional items and tax rose 34.7% year-on-year to ₹308.1 crore from ₹228.7 crore in the same period last year.
Revenue increased by 17.9% YoY to ₹949.4 crore compared to ₹805.3 crore in Q3 FY24, reflecting sustained demand for its core brands.
EBITDA jumped 33.8% to ₹291.9 crore from ₹218.1 crore, while EBITDA margin expanded to 30.7% from 27.1% in the year-ago period.
Key segment highlights:
General Medicines Portfolio:
GSK Pharma’s flagship brands such as Augmentin, Ceftum, and T-Bact continued to gain market share, reinforcing their leadership positions.
Respiratory Portfolio: The innovative respiratory portfolio, led by Nucala and Trelegy, witnessed strong growth, enhancing patient access across India.
Vaccines Business: The company maintained its leadership in the self-pay private market for paediatric vaccines. Additionally, the adult vaccines segment gained traction, with Shingrix (Herpes Zoster Vaccine – recombinant, adjuvanted) driving increased adoption and expansion of adult immunisation in India.
Bhushan Akshikar, Managing Director of GlaxoSmithKline Pharmaceuticals, expressed confidence in the company’s growth trajectory. “Our strong third-quarter results reflect our unwavering commitment to delivering innovative healthcare solutions to patients across India,” he said.
Also read: Samvardhana Motherson Q3 profit surges 62% YoY, margin beats estimates
By focusing on core brands and accelerating digital transformation through innovative go-to-market strategies, the pharma company continues to strengthen its market presence while ensuring broader access to medicines and vaccines, he added.
Ahead of the earnings announcement, shares of GSK Pharma closed at ₹2,017.75, up 1.11% on the BSE.
[ad_2]
Source link